AB Science & Daiichi Try Their Luck Again With EU Filings
Executive Summary
The sponsors of Alsitek and quizartinib are hoping that new data generated for the drugs will resolve the concerns raised by the European Medicines Agency when it previously rejected the products for marketing in the EU.
You may also be interested in...
New EU Filings
Givinostat, Italfarmaco’s investigational treatment for Duchenne muscular dystrophy, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
New EU Filings
Zolbetuximab, Astellas’ Claudin 18.2-targeting cancer drug, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
New EU Filings
Fruquintinib, Takeda/Hutchmed’s treatment for adult patients with previously treated metastatic colorectal cancer, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.